CUROGEN has been awarded a 2024 research grant from the Korea Drug Development Fund (KDDF) under the "Expanding Drug Development Foundations" category. This project focuses on lead-compound-stage assets and will run from April 2024 to April 2026. The total grant amount is 800 million KRW.
 

This award adds to CUROGEN’s growing portfolio of funded research initiatives and underscores our commitment to innovation in early-stage drug discovery.